The rheumatoid arthritis market has exploded in recent years, producing some of big pharma's best-selling blockbuster drugs. AbbVie's (NYSE: ABBV ) Humira hit sales of more than $9 billion to lead the market last year, but competitors from other companies -- such as�Johnson & Johnson's (NYSE: JNJ ) Remicade, which hauled in more than $6 billion last year to rank among the top drugs in the industry -- have thrived in a crowded but lucrative immunology field.
Humira faces a patent expiration soon, however, and competition continues to heat up in this space. GlaxoSmithKline (NYSE: GSK ) is the latest firm to eye the arthritis market after it agreed to a licensing deal with German biotech firm MorphoSys (NASDAQOTH: MPSYF ) this week for its developmental immunology therapy MOR103. Glaxo's pipeline is sizable and solid, but will this deal brew another blockbuster for the firm's future? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss what you need to know.
Top 10 Valued Companies To Buy For 2015: LDK Solar Co. Ltd.(LDK)
LDK Solar Co., Ltd., together with its subsidiaries, engages in the design, development, manufacture, and marketing of photovoltaic (PV) products; and development of power plant projects. It offers solar-grade and semiconductor-grade polysilicon; and multicrystalline and monocrystalline solar wafers to the manufacturers of solar cells and solar modules. The company also provides wafer processing services to monocrystalline and multicrystalline solar cell and module manufacturers; and sells silicon materials, such as ingots and polysilicon scraps. In addition, it engages in the production and sale of solar cells and modules to developers, distributors, and system integrators; and design and development of solar power projects in Europe, the United States, and China, as well as provides engineering, procurement, and construction services. LDK Solar Co., Ltd. operates in Europe, the Asia Pacific, and North America. The company was founded in 2005 and is based in Xinyu City, t he People?s Republic of China.
Advisors' Opinion:- [By Travis Hoium]
LDK Solar (NYSE: LDK ) is on the brink of failure after another terrible performance in the first quarter. The company is paying more than half of its revenue in interest payments and is begging creditors to refinance debt so that it can stay alive. For equity investors there is little upside given the company's high debt load and massive losses. Fool.com contributor Travis Hoium weighs in on LDK's situation.
- [By Travis Hoium]
Who wins?
It's important to remember that the only change from two months ago is that Chinese panels will have a higher price. So, companies such as LDK Solar (NYSE: LDK ) , who were trying to compete on price alone, will likely be left in the dust. Investors should focus on higher-quality manufacturers like Yingli Green Energy, Trina Solar, and Canadian Solar (NASDAQ: CSIQ ) as potential winners from the negotiated solar deal. - [By Paul Ausick]
Chinese solar companies are a different story. Many manufacture their own silicon wafers and sell silicon to other makers. Trina Solar Ltd. (NYSE: TSL), LDK Solar Co. Ltd. (NYSE: LDK), JA Solar Holdings Co. Ltd. (NASDAQ: JASO) and Canadian Solar Inc. (NASDAQ: CSIQ) all manufacture and sell solar ingots, wafers or cells.
- [By Dan Caplinger]
Next Tuesday, LDK Solar (NYSE: LDK ) will release its latest quarterly results. Lately, investors have had to wonder whether the Chinese solar company will be able to continue operating, as LDK is one of many solar companies in the emerging-market nation going through a cash crunch due to large losses.
Top 5 Up And Coming Stocks For 2014: EMCOR Group Inc. (EME)
EMCOR Group, Inc. provides electrical and mechanical construction, and facilities services primarily to commercial, industrial, utility, and institutional customers in the United States, the United Kingdom, and internationally. The company offers various electrical and mechanical systems, including electric power transmission and distribution systems, such as power cables, conduits, distribution panels, transformers, generators, uninterruptible power supply systems, and related switch gear and controls; premises electrical and lighting systems, including fixtures and controls; low-voltage systems comprising fire alarms, and security and process control systems; voice and data communications systems, including fiber-optic and low-voltage cabling systems; and roadway and transit lighting and fiber-optic lines. It also provides heating, ventilation, air conditioning, refrigeration, and clean-room process ventilation systems; fire protection systems; plumbing, processing, and piping systems; controls and filtration systems; water and wastewater treatment systems; central plant heating and cooling systems; cranes and rigging; millwrighting; and steel fabrication, erection, and welding systems. In addition, the company offers facilities services comprising industrial maintenance and services; outage services to utilities and industrial plants; commercial and government site-based operations and maintenance; military base operations support; mobile mechanical maintenance and services; floor care and janitorial; landscaping, lot sweeping, and snow removal; facilities and vendor management; call center; building systems installation and support; and technical consulting and diagnostic services. Further, it provides small modification and retrofit projects; retrofit projects; and program development, management, and maintenance services for energy systems. EMCOR Group, Inc. was founded in 1966 and is headquartered in Norwalk, Connecticut.
Advisors' Opinion:- [By Eric Volkman]
EMCOR Group (NYSE: EME ) is growing the old-fashioned way -- with the purchase of outside assets. The company announced�that it will acquire the privately held RepconStrickland, a Texas-based firm it describes as "a leading provider of recurring turnaround and specialty services to the North American refinery and petrochemical markets."
- [By Seth Jayson]
When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to EMCOR Group (NYSE: EME ) .
Top 5 Up And Coming Stocks For 2014: Theragenics Corporation(TGX)
Theragenics Corporation operates as a medical device company serving the cancer treatment and surgical products markets primarily in the United States and Europe. It operates through two segments, Surgical Products and Brachytherapy Seed. The Surgical Products segment manufactures, markets, and sells disposable devices primarily utilized in surgical procedures. It offers wound closure products, including sutures, needles, and other surgical products; vascular access products comprising introducer sheaths, guidewires, and accessories; and specialty needles consisting of coaxial, biopsy, brachytherapy, guidewire introducer, spinal, and disposable veress, as well as access trocars and other needle-based products. This segment?s products are used in various markets and applications, such as interventional cardiology and radiology, vascular surgery, orthopedics, plastic surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. The Brachytherapy See d segment manufactures, markets, and sells TheraSeed and I-Seed, which are FDA-cleared devices for treatment of solid localized tumors and localized prostate cancer. The company sells its products primarily to physicians, hospitals and other healthcare providers, original equipment manufacturers, and to a network of distributors. Theragenics Corporation was founded in 1981 and is based in Buford, Georgia.
Advisors' Opinion:- [By James E. Brumley]
I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).
Top 5 Up And Coming Stocks For 2014: Acura Pharmaceuticals Inc.(ACUR)
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable active ingredients, such as tranquillizers, stimulants, sedatives, and decongestants. The company offers OXECTA Tablets CII, which are oral formulations of oxycodone HCl for the management of acute and chronic moderate to severe pain; and Impede PSE, a pseudoephedrine hydrochloride tablet product candidate. It is also developing opioid analgesic product candidates, which would be used to relieve pain while discouraging common methods of opioid product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. In addition, the company investigates and develops mechanisms to incorporate abuse deterrent features into abused and misused pharmaceutical products using its Impede Technology. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize certain opioid analgesic products utilizing the company?s proprietary Aversion Technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.
Advisors' Opinion:- [By Rick Munarriz]
Thursday
Acura Pharmaceuticas (NASDAQ: ACUR ) checks in on Thursday. Drugmakers use Acura's Aversion and Impede technologies to create abuse-deterrent treatments. In short, if an abuser tries to extract the active ingredient of a drug to heighten addictive experiences, Acura's technologies kick in to make the whole dose unusable. - [By John Udovich]
On Tuesday, small cap specialty pharmaceutical company�Acura Pharmaceuticals, Inc (NASDAQ: ACUR) surged 27.52% to $1.90 on no apparent news beyond a speculative Seeking Alpha article that talked about certain catalysts����meaning its worth taking a closer look at the company to see what�� going on and whether shares could move higher.�
No comments:
Post a Comment